NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Christina I TsienStephanie L PughAdam P DickerJeffrey J RaizerMartha M MatuszakEnrico C LallanaJiayi HuangOzer AlganNimisha DebLorraine PortelanceJohn L VillanoJohn T HammKevin S OhArif N AliMichelle M KimScott M LindhorstMinesh P MehtaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
To our knowledge, NRG Oncology/RTOG1205 is the first prospective, randomized multi-institutional study to evaluate the safety and efficacy of re-RT in recurrent GBM using modern RT techniques. Overall, re-RT was shown to be safe and well tolerated. BEV + RT demonstrated a clinically meaningful improvement in PFS, specifically the 6-month PFS rate but no difference in OS.